AMG 827 in Subjects With Psoriatic Arthritis
Public ClinicalTrials.gov record NCT01516957. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blinded, Placebo-controlled, Multiple-dose Study With an Open Label Extension to Evaluate the Safety and Efficacy of AMG 827 in Subjects With Psoriatic Arthritis.
Study identification
- NCT ID
- NCT01516957
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Bausch Health Americas, Inc.
- Industry
- Enrollment
- 168 participants
Conditions and interventions
Conditions
Interventions
- AMG 827 140 Drug
- AMG 827 210 Drug
- AMG 827 280 Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 30, 2011
- Primary completion
- Aug 31, 2012
- Completion
- Aug 31, 2015
- Last update posted
- Aug 26, 2020
2011 – 2015
United States locations
- U.S. sites
- 22
- U.S. states
- 13
- U.S. cities
- 22
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Peoria | Arizona | 85381 | — |
| Research Site | Scottsdale | Arizona | 85258 | — |
| Research Site | Tucson | Arizona | 85711 | — |
| Research Site | Hemet | California | 92543 | — |
| Research Site | Huntington Beach | California | 92646 | — |
| Research Site | La Jolla | California | 92037 | — |
| Research Site | Los Angeles | California | 90095 | — |
| Research Site | Palm Desert | California | 92260 | — |
| Research Site | Palo Alto | California | 94304 | — |
| Research Site | Victorville | California | 92395 | — |
| Research Site | Sarasota | Florida | 34239 | — |
| Research Site | Boise | Idaho | 83702 | — |
| Research Site | Lexington | Kentucky | 40504 | — |
| Research Site | Baton Rouge | Louisiana | 70809 | — |
| Research Site | Frederick | Maryland | 21702 | — |
| Research Site | Grand Rapids | Michigan | 49546 | — |
| Research Site | Lansing | Michigan | 48910 | — |
| Research Site | Lebanon | New Hampshire | 03756 | — |
| Research Site | Rochester | New York | 14642 | — |
| Research Site | Portland | Oregon | 97239 | — |
| Research Site | Duncansville | Pennsylvania | 16635 | — |
| Research Site | Seattle | Washington | 98122 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 9 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01516957, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 26, 2020 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01516957 live on ClinicalTrials.gov.